Long Term Debt Summary of Oncolytics Biotech Inc.

Oncolytics Biotech Inc.'s latest annual long term debt in 2023 was 290 Thousand CAD , up 84.71% from previous year.
Oncolytics Biotech Inc.'s latest quarterly long term debt in 2024 Q2 was 891 Thousand CAD , down 0.0% from previous quarter.
Oncolytics Biotech Inc. reported annual long term debt of 157 Thousand CAD in 2022, down -56.52% from previous year.
Oncolytics Biotech Inc. reported annual long term debt of 361.08 Thousand CAD in 2021, up 135.73% from previous year.
Oncolytics Biotech Inc. reported quarterly long term debt of 891 Thousand CAD for 2024 Q2, down 0.0% from previous quarter.
Oncolytics Biotech Inc. reported quarterly long term debt of 378 Thousand CAD for 2023 Q1, up 140.76% from previous quarter.

Annual Long Term Debt Chart of Oncolytics Biotech Inc. (2023 - 1999)

Historical Annual Long Term Debt of Oncolytics Biotech Inc. (2023 - 1999)

Year	Long Term Debt	Long Term Debt Growth
2023	290 Thousand CAD	84.71%
2022	157 Thousand CAD	-56.52%
2021	361.08 Thousand CAD	135.73%
2020	153.17 Thousand CAD	-7.96%
2019	166.42 Thousand CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%
2016	- CAD	0.0%
2015	- CAD	0.0%
2014	- CAD	0.0%
2013	- CAD	0.0%
2012	- CAD	0.0%
2011	- CAD	0.0%
2010	- CAD	0.0%
2009	- CAD	0.0%
2008	- CAD	0.0%
2007	- CAD	-100.0%
2006	150 Thousand CAD	0.0%
2005	150 Thousand CAD	0.0%
2004	150 Thousand CAD	0.0%
2003	150 Thousand CAD	0.0%
2002	150 Thousand CAD	0.0%
2001	150 Thousand CAD	0.0%
2000	150 Thousand CAD	0.0%
1999	150 Thousand CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	948 Thousand CAD	0.0%
2024 Q2	891 Thousand CAD	0.0%
2023 Q1	378 Thousand CAD	140.76%
2023 FY	290 Thousand CAD	84.71%
2023 Q4	290 Thousand CAD	-10.22%
2023 Q3	323 Thousand CAD	-6.65%
2023 Q2	346 Thousand CAD	-8.47%
2022 Q4	157 Thousand CAD	-5.37%
2022 Q1	276.64 Thousand CAD	-23.39%
2022 Q2	192.09 Thousand CAD	-30.56%
2022 FY	157 Thousand CAD	-56.52%
2022 Q3	165.91 Thousand CAD	-13.63%
2021 Q1	371.97 Thousand CAD	142.84%
2021 Q2	510.36 Thousand CAD	37.21%
2021 Q3	441.98 Thousand CAD	-13.4%
2021 Q4	361.08 Thousand CAD	-18.3%
2021 FY	361.08 Thousand CAD	135.73%
2020 FY	153.17 Thousand CAD	-7.96%
2020 Q4	153.17 Thousand CAD	-16.8%
2020 Q2	17.39 Thousand CAD	-81.36%
2020 Q3	184.1 Thousand CAD	958.15%
2020 Q1	93.35 Thousand CAD	-43.91%
2019 Q1	420.22 Thousand CAD	0.0%
2019 Q3	245.7 Thousand CAD	-22.46%
2019 Q4	166.42 Thousand CAD	-32.26%
2019 FY	166.42 Thousand CAD	0.0%
2019 Q2	316.85 Thousand CAD	-24.6%
2018 Q1	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q4	- CAD	0.0%
2018 Q3	- CAD	0.0%
2018 Q2	- CAD	0.0%
2017 Q3	- CAD	0.0%
2017 FY	- CAD	0.0%
2017 Q1	- CAD	0.0%
2017 Q4	- CAD	0.0%
2017 Q2	- CAD	0.0%
2016 Q1	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 FY	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q1	- CAD	0.0%
2015 FY	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 Q2	- CAD	0.0%
2014 Q4	- CAD	0.0%
2014 Q2	- CAD	0.0%
2014 Q1	- CAD	0.0%
2014 FY	- CAD	0.0%
2014 Q3	- CAD	0.0%
2013 Q2	- CAD	0.0%
2013 Q1	- CAD	0.0%
2013 Q4	- CAD	0.0%
2013 Q3	- CAD	0.0%
2013 FY	- CAD	0.0%
2012 Q1	- CAD	0.0%
2012 Q4	- CAD	0.0%
2012 FY	- CAD	0.0%
2012 Q2	- CAD	0.0%
2012 Q3	- CAD	0.0%
2011 Q1	- CAD	0.0%
2011 FY	- CAD	0.0%
2011 Q4	- CAD	0.0%
2011 Q3	- CAD	0.0%
2011 Q2	- CAD	0.0%
2010 Q2	- CAD	0.0%
2010 Q3	- CAD	0.0%
2010 Q4	- CAD	0.0%
2010 FY	- CAD	0.0%
2010 Q1	- CAD	0.0%
2009 Q2	- CAD	0.0%
2009 FY	- CAD	0.0%
2009 Q4	- CAD	0.0%
2009 Q3	- CAD	0.0%
2009 Q1	- CAD	0.0%
2008 Q3	- CAD	0.0%
2008 FY	- CAD	0.0%
2008 Q1	- CAD	0.0%
2008 Q2	- CAD	0.0%
2008 Q4	- CAD	0.0%
2007 Q2	- CAD	0.0%
2007 Q3	- CAD	0.0%
2007 FY	- CAD	-100.0%
2007 Q1	- CAD	-100.0%
2007 Q4	- CAD	0.0%
2006 Q2	150 Thousand CAD	0.0%
2006 FY	150 Thousand CAD	0.0%
2006 Q4	150 Thousand CAD	0.0%
2006 Q3	150 Thousand CAD	0.0%
2006 Q1	150 Thousand CAD	0.0%
2005 Q1	150 Thousand CAD	0.0%
2005 Q3	174.21 Thousand CAD	16.14%
2005 Q2	150 Thousand CAD	0.0%
2005 Q4	150 Thousand CAD	-13.9%
2005 FY	150 Thousand CAD	0.0%
2004 Q1	150 Thousand CAD	0.0%
2004 Q2	150 Thousand CAD	0.0%
2004 Q3	150 Thousand CAD	0.0%
2004 Q4	150 Thousand CAD	0.0%
2004 FY	150 Thousand CAD	0.0%
2003 Q1	150 Thousand CAD	0.0%
2003 Q2	150 Thousand CAD	0.0%
2003 Q3	150 Thousand CAD	0.0%
2003 Q4	150 Thousand CAD	0.0%
2003 FY	150 Thousand CAD	0.0%
2002 Q1	150 Thousand CAD	0.0%
2002 Q3	161.9 Thousand CAD	7.94%
2002 Q4	150 Thousand CAD	-7.35%
2002 FY	150 Thousand CAD	0.0%
2002 Q2	150 Thousand CAD	0.0%
2001 FY	150 Thousand CAD	0.0%
2001 Q1	- CAD	-100.0%
2001 Q4	150 Thousand CAD	0.0%
2001 Q2	150 Thousand CAD	0.0%
2001 Q3	150 Thousand CAD	0.0%
2000 Q4	150 Thousand CAD	0.0%
2000 Q2	150 Thousand CAD	0.0%
2000 FY	150 Thousand CAD	0.0%
2000 Q1	150 Thousand CAD	0.0%
2000 Q3	150 Thousand CAD	0.0%
1999 FY	150 Thousand CAD	0.0%

Peer Long Term Debt Comparison of Oncolytics Biotech Inc.

Name	Long Term Debt	Long Term Debt Difference
Appili Therapeutics Inc.	875.2 Thousand CAD	66.865%
Eupraxia Pharmaceuticals Inc.	- CAD	-Infinity%
Helix BioPharma Corp.	- CAD	-Infinity%
Microbix Biosystems Inc.	6.37 Million CAD	95.454%
Medicenna Therapeutics Corp.	- CAD	-Infinity%
Satellos Bioscience Inc.	- CAD	-Infinity%
Sernova Corp.	- CAD	-Infinity%

Global Stocks Search

Oncolytics Biotech Inc. (ONC.TO)

Long Term Debt Summary of Oncolytics Biotech Inc.

Annual Long Term Debt Chart of Oncolytics Biotech Inc. (2023 - 1999)

Historical Annual Long Term Debt of Oncolytics Biotech Inc. (2023 - 1999)

Peer Long Term Debt Comparison of Oncolytics Biotech Inc.